Article Text

Download PDFPDF
Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin
  1. Ritesh Gupta1,
  2. Amerta Ghosh1,
  3. Anoop Misra1,2,3
  1. 1 Department of Diabetes, Metabolic Diseases and Endocrinology, Fortis CDOC Hospital, New Delhi, India
  2. 2 National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India
  3. 3 Diabetes Foundation India, New Delhi, India
  1. Correspondence to Dr Ritesh Gupta, Fortis CDOC Hospital, New Delhi 110048, India; riteshgupta72{at}

Statistics from

Despite the fact that sodium glucose cotransporter 2 inhibitors (SGLT2-i) have proven efficacy in controlling hyperglycaemia and reducing cardiovascular outcomes, their adverse effects on the urogenital tract remain a concern.1 We report a patient with acute unilateral emphysematous pyelonephritis possibly associated with canagliflozin.

A 59-year-old woman presented to the emergency department with high-grade fever with chills and rigours for 1 day. She also complained of painful micturition and dull pain in flanks. She was known to have diabetes for 14 years, and her antihyperglycaemic medications included gliclazide 80 mg daily, linagliptin 5 mg daily, metformin 1 g daily and canagliflozin 100 mg daily. Notably, canagliflozin had been started about 11 months before …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.